Skip to main content
Terug
Watch Compare

SUTRO BIOPHARMA, INC.

Datakwaliteit: 100%
STRO
NASDAQ Manufacturing Chemicals
€ 25,86
▼ € 0,90 (-3,36%)
Marktkapitalisatie: 428,43 M
Prijs
€ 25,86
Marktkapitalisatie
428,43 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue grew 13,44% annually over 5 years — strong growth
Negative free cash flow of -177,23 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 51,74%

Groei

Revenue Growth (5Y)
13,44%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)65,18%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-76,78%
Net Margin-186,45%
Op. Margin-154,53%

Veiligheid

Debt / Equity
N/A
Current Ratio2,53
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-2,24 | -10,43
Onder sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -2,2 -1,5
P/B — 1,6
ROE % — -54,0
Net Margin % -186,5 -41,5
Rev Growth 5Y % 13,4 1,8
D/E — 0,3

Koersdoel Analisten

9 analisten
Buy
Huidig
€ 25,86
+16.4%
Koersdoel
€ 30,11
€ 9,00
€ 28,00
€ 55,00
Vooruitzicht
Forward K/W -10,43
Forward WPA -€ 2,48
Omzet Sch. 24,87 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 2,48
-€ 4,56 – -€ 0,40
 24,87 M 2
FY2026 -€ 6,71
-€ 6,71 – -€ 6,71
 35,36 M 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 4,43 -€ 4,88 -10,2%
Q32025 -€ 3,55 -€ 5,57 -57,0%
Q22025 -€ 5,30 -€ 1,40 +73,6%
Q12025 N/A -€ 8,02 —

ETFs Holding This Stock

CNCR CNCR
0,76% weight
GCSSX GCSSX
0,07% weight
GCSAX GCSAX
0,07% weight
GCSCX GCSCX
0,07% weight
GCSIX GCSIX
0,07% weight
GDSTX GDSTX
0,07% weight
GCSUX GCSUX
0,07% weight
GMAPX GMAPX
0,07% weight
GDSRX GDSRX
0,07% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 65,18% Revenue Growth (3Y) -18,35%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 13,44% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 102,48 M Net Income (TTM) -191,09 M
ROE N/A ROA -80,97%
Gross Margin N/A Operating Margin -154,53%
Net Margin -186,45% Free Cash Flow (TTM) -177,23 M
ROIC -76,78% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,53
Interest Coverage N/A Asset Turnover 0,43
Working Capital 110,22 M Tangible Book Value -87,27 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,24 Forward P/E -10,43
P/B Ratio N/A P/S Ratio 4,18
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 17,23 Fwd Earnings Yield N/A
FCF Yield -41,37%
Market Cap 428,43 M Enterprise Value 362,50 M
Per Share
EPS (Diluted TTM) -22,49 Revenue / Share 6,19
FCF / Share -10,70 OCF / Share -10,70
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 92,75%
SBC-Adj. FCF -196,13 M Growth Momentum 51,74

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 102,48 M 62,04 M 153,73 M 67,77 M 61,88 M
Net Income -191,09 M -227,46 M -106,79 M -119,20 M -105,54 M
EPS (Diluted) -22,49 -2,96 -1,78 -2,35 —
Gross Profit — — — — —
Operating Income -158,37 M -238,45 M -89,28 M -128,94 M -98,52 M
EBITDA — — — — —
R&D Expenses 166,42 M 252,04 M 180,43 M 137,17 M 104,40 M
SG&A Expenses — — — — —
D&A 7,32 M 7,22 M 6,82 M 5,69 M 4,84 M
Interest Expense — — 1,30 M 2,40 M 2,60 M
Income Tax -93.000,0 2,36 M 18,19 M 2,50 M 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 173,83 M 387,21 M 470,74 M 406,94 M 341,41 M
Total Liabilities 306,28 M 342,61 M 321,09 M 189,90 M 88,84 M
Shareholders' Equity -132,45 M 44,60 M 149,65 M 217,05 M 252,56 M
Total Debt — — 4,06 M 16,27 M 25,11 M
Cash & Equivalents 58,13 M 190,30 M 69,27 M 47,25 M 30,41 M
Current Assets 150,93 M 343,31 M 421,54 M 353,15 M 218,52 M
Current Liabilities 75,13 M 131,89 M 93,75 M 66,55 M 41,74 M